Express . . . Strong teamed up to develop innovative cancer therapies with Sanofi and MD Anderson Cancer Center.

Sanofi and MD Anderson Cancer Center at the University of Texas today announced a five-year strategic partnership to accelerate the development of research-based therapies for cancer patients, including targeted therapy and immunotherapy.the alliance will combine the clinical trial infrastructure of MD Anderson Cancer Center and the experimental treatment pipeline of Sanofi to lead biomarker driven clinical research to better understand how new cancer drugs work."our goal is to improve the outcomes of a range of patients with refractory cancer, and the best way to achieve this goal is through an in-depth understanding of how new drugs are working," said Peter, global head of innovation in oncology and pediatrics at Sanofi "The alliance draws on the MD Anderson Cancer Center's flexible strategy for conducting early clinical trials, its laboratory capabilities and extensive scientific expertise," said Dr. Adamson.this will allow us to make decisions faster and help us more accurately identify potential new combinations and indications.this will save valuable time and help us expand the range of patients who may benefit from our treatment."MD Anderson Cancer Center manages one of the largest cancer clinical trials in the United States, with a comprehensive platform for tissue collection, molecular and immune analysis and data analysis.this infrastructure enables a comprehensive study of tumor samples collected before, during and after treatment to discover valuable insights, simplify patient screening, and accelerate the identification of new treatment combinations and indications."clinical trials not only help us advance new life-saving treatments for patients in need, they also provide us with valuable information on which treatments may be more effective for which patients," said funda, MD Anderson Cancer Center chair of research cancer therapy "We are pleased to work with Sanofi to accelerate the development of innovative cancer therapy pipelines," said Dr. meric bernstam."the new alliance will also support the investigation of additional indications and combinations of drugs for research projects already in clinical practice.scientists from Sanofi and MD Anderson Cancer Center will cooperate on the experimental design, applying a core set of biomarkers and detection methods.the joint project will also apply the new candidate drugs developed by Sanofi to existing tumor samples to obtain further data on their effects at different stages of disease.new findings, as well as large-scale molecular and phenotypic data sets, will be applied to the design of new transformation studies for specific Sanofi molecules in research and guide the selection of indications.the cooperation is expected to start the first batch of projects in the summer of 2020.References: [1] Sanofi and MD Anderson announcement strategic collaboration to accelerate oncology research and development. Retrieved July 14, 2020, from note: This paper aims to introduce the progress of medical and health research, not to recommend treatment options.if you need guidance on treatment plan, please go to a regular hospital.